Willie Quinn is a life sciences executive with a passion for making a difference. Mr. Quinn is CFO and SVP Corporate Development at Sunesis Pharmaceuticals (NASDAQ:SNSS), a clinical-stage biopharmaceutical company developing new oncology therapeutics. Previously, he was CEO and co-founder of Bullet Bio, a private company developing cancer immunotherapies based on technology invented at Stanford University. Prior to Bullet Bio, Willie ran Corporate Development for Jazz Pharmaceuticals, a public specialty pharmaceutical company with experience developing and commercializing drugs for orphan indications (indications with fewer than 200,000 patients in the U.S.). Willie joined Jazz Pharmaceuticals in 2003 and actively participated in the creation of their first business plan, working in various functions such as business development, strategy, and finance over his 8 years at the company. Prior to Jazz Pharmaceuticals, Willie was COO and CFO at Novation Biosciences, a venture-backed startup developing software to extract meaningful information from microarray data.

Willie has an MBA from the Stanford Graduate School of Business and an MA and a BA from Stanford University.